BioNTech Inks Potential $1B Deal with MediLink for Cancer-Focused ADCs

cafead

Administrator
Staff member
  • cafead   Oct 13, 2023 at 12:12: PM
via BioNTech on Thursday entered into a strategic research collaboration and worldwide licensing agreement with Suzhou-based biotech MediLink Therapeutics to develop next-generation antibody-drug conjugates for cancer.

article source